When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19
暂无分享,去创建一个
K. Steadman | Solomon Abrha | Jackson Thomas | D. Erku | Kathryn J. Steadman | Daniel A. Erku | Sewunet A. Belachew | Solomon Abrha | Mahipal Sinnollareddy | Jackson Thomas | Wubshet H. Tesfaye | S. A. Belachew | W. Tesfaye | M. Sinnollareddy | Daniel A. Erku
[1] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[2] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[3] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[4] gui-qiang Wang,et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option , 2020, Journal of medical virology.
[5] Joshua D. Brown,et al. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine , 2020, Research in Social and Administrative Pharmacy.
[6] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[7] J. Klingström,et al. Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.
[8] Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment , 2020, Case Medical Research.
[9] Xiang Xie,et al. COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.
[10] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia , 2020, Case Medical Research.
[12] Michael Roth,et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.
[13] Jordan G Sheppard,et al. Community pharmacists and communication in the time of COVID-19: Applying the health belief model , 2020, Research in Social and Administrative Pharmacy.
[14] S. Ōmura,et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process , 2019, The Journal of Antibiotics.
[15] Wu Zhong,et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.
[16] P. Middleton,et al. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic , 2020, Trends in Pharmacological Sciences.
[17] D. Jans,et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.
[18] N. Dong,et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China , 2020, bioRxiv.
[19] E. Chorin,et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin , 2020, Nature Medicine.
[20] P. Guérin,et al. The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world? , 2020, F1000Research.
[21] Xuhui Huang,et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.
[22] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[23] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[24] COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, Allergy.
[25] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[26] Centers for Disease Control and Prevention CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[27] Catherine S. K. Cheung,et al. Anti‐inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial , 2017, Antiviral research.
[28] M. Martínez. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.
[29] Sharon Einav,et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.
[30] C. Cheung,et al. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) , 2020, Journal of General Internal Medicine.
[31] Philippe Brouqui,et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.
[32] J. Avorn,et al. Drug Evaluation during the Covid-19 Pandemic. , 2020, The New England journal of medicine.
[33] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[34] A. Salazar-Ospina,et al. How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal , 2020, Research in Social and Administrative Pharmacy.
[35] Hongzhou Lu,et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.
[36] P. Ravaud,et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial , 2020, medRxiv.
[37] Elsevier Sdol,et al. Research in Social and Administrative Pharmacy , 2009 .
[38] A. Khan,et al. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief , 2020, Expert review of respiratory medicine.
[39] J. Wetterslev,et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. , 2016, The Cochrane database of systematic reviews.
[40] Xiao-yan Liu,et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection , 2020, medRxiv.
[41] Bo Chen,et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.
[42] Jun Zhang,et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression , 2020, International Journal of Infectious Diseases.
[43] J. Jackson,et al. From the Editors’ Desk: The Importance of Screening for Depression in Primary Care , 2019, Journal of General Internal Medicine.
[44] J. Low,et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.
[45] D. Raoult,et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.
[46] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[47] O. Al-Quteimat,et al. SARS-CoV-2 outbreak: How can pharmacists help? , 2020, Research in Social and Administrative Pharmacy.
[48] M. Cascella,et al. Features, Evaluation and Treatment Coronavirus (COVID-19) , 2020 .
[49] Alexis Jacquier,et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.
[50] Z. Hong,et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.
[51] F. Hayden,et al. Macrolides in critically ill patients with Middle East Respiratory Syndrome , 2019, International Journal of Infectious Diseases.
[52] B. Bozkurt,et al. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 , 2020, Journal of Cardiac Failure.
[53] L. Nissen,et al. Pharmacist role in vaccination: Evidence and challenges. , 2019, Vaccine.
[54] S. P. Akpabio. World Health Organisation , 1983, British Dental Journal.
[55] D. Raoult,et al. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century , 2007, International Journal of Antimicrobial Agents.
[56] Jing Yuan,et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.
[57] W. Liu,et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.
[58] Alex A. Pollen,et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin , 2016, Proceedings of the National Academy of Sciences.
[59] G. Cheng,et al. Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses , 2019, Antimicrobial Agents and Chemotherapy.
[60] Huan Li,et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China , 2020, medRxiv.
[61] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[62] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[63] C. Hughes,et al. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis , 2020, Research in Social and Administrative Pharmacy.
[64] S. Kosari,et al. Fake News: Medicines Misinformation by the Media , 2018, Clinical pharmacology and therapeutics.
[65] Zhan Zhang,et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.